Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA)

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). / Stenvang, Jan; Pfundheller, Henrik M; Lykkesfeldt, Anne E.

In: Oligonucleotides, Vol. 14, No. 2, 2004, p. 147-56.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Stenvang, J, Pfundheller, HM & Lykkesfeldt, AE 2004, 'Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA)', Oligonucleotides, vol. 14, no. 2, pp. 147-56. https://doi.org/10.1089/1545457041526281

APA

Stenvang, J., Pfundheller, H. M., & Lykkesfeldt, A. E. (2004). Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides, 14(2), 147-56. https://doi.org/10.1089/1545457041526281

Vancouver

Stenvang J, Pfundheller HM, Lykkesfeldt AE. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides. 2004;14(2):147-56. https://doi.org/10.1089/1545457041526281

Author

Stenvang, Jan ; Pfundheller, Henrik M ; Lykkesfeldt, Anne E. / Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). In: Oligonucleotides. 2004 ; Vol. 14, No. 2. pp. 147-56.

Bibtex

@article{721e71a8f90a425b85810d30c94c8b6d,
title = "Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA)",
abstract = "Locked nucleic acid (LNA) is a nucleic acid analog with very high affinity to complementary RNA and a promising compound in the field of antisense research. The intracellular localization and quantitative uptake of oligonucleotides containing LNA were found to be equivalent to those of phosphorothioate oligonucleotides (PS AONs). The antisense efficiency of LNA-containing oligonucleotides was systematically compared with standard PS AONs targeting expression of two endogenous proteins in the human breast cancer cell line MCF-7, namely, the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and the estrogen receptor alpha (ERalpha). For downregulation of both target proteins, the most efficient design was achieved with oligonucleotides containing LNA monomers in the extremities and a central gap of PS-linked DNA monomers, so called LNA gapmers. Such LNA gapmers caused more potent downregulation of the targeted proteins than PS AONs, whereas fully modified LNA AONs or LNA mixmers (LNA nucleotides interspersed) were inactive.",
keywords = "Cell Cycle Proteins, Cell Line, Cyclin-Dependent Kinase Inhibitor p21, Down-Regulation, Estrogen Receptor alpha, Humans, Oligonucleotides, Oligonucleotides, Antisense",
author = "Jan Stenvang and Pfundheller, {Henrik M} and Lykkesfeldt, {Anne E}",
year = "2004",
doi = "10.1089/1545457041526281",
language = "English",
volume = "14",
pages = "147--56",
journal = "Nucleic Acid Therapeutics",
issn = "2159-3337",
publisher = "Mary AnnLiebert, Inc. Publishers",
number = "2",

}

RIS

TY - JOUR

T1 - Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA)

AU - Stenvang, Jan

AU - Pfundheller, Henrik M

AU - Lykkesfeldt, Anne E

PY - 2004

Y1 - 2004

N2 - Locked nucleic acid (LNA) is a nucleic acid analog with very high affinity to complementary RNA and a promising compound in the field of antisense research. The intracellular localization and quantitative uptake of oligonucleotides containing LNA were found to be equivalent to those of phosphorothioate oligonucleotides (PS AONs). The antisense efficiency of LNA-containing oligonucleotides was systematically compared with standard PS AONs targeting expression of two endogenous proteins in the human breast cancer cell line MCF-7, namely, the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and the estrogen receptor alpha (ERalpha). For downregulation of both target proteins, the most efficient design was achieved with oligonucleotides containing LNA monomers in the extremities and a central gap of PS-linked DNA monomers, so called LNA gapmers. Such LNA gapmers caused more potent downregulation of the targeted proteins than PS AONs, whereas fully modified LNA AONs or LNA mixmers (LNA nucleotides interspersed) were inactive.

AB - Locked nucleic acid (LNA) is a nucleic acid analog with very high affinity to complementary RNA and a promising compound in the field of antisense research. The intracellular localization and quantitative uptake of oligonucleotides containing LNA were found to be equivalent to those of phosphorothioate oligonucleotides (PS AONs). The antisense efficiency of LNA-containing oligonucleotides was systematically compared with standard PS AONs targeting expression of two endogenous proteins in the human breast cancer cell line MCF-7, namely, the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and the estrogen receptor alpha (ERalpha). For downregulation of both target proteins, the most efficient design was achieved with oligonucleotides containing LNA monomers in the extremities and a central gap of PS-linked DNA monomers, so called LNA gapmers. Such LNA gapmers caused more potent downregulation of the targeted proteins than PS AONs, whereas fully modified LNA AONs or LNA mixmers (LNA nucleotides interspersed) were inactive.

KW - Cell Cycle Proteins

KW - Cell Line

KW - Cyclin-Dependent Kinase Inhibitor p21

KW - Down-Regulation

KW - Estrogen Receptor alpha

KW - Humans

KW - Oligonucleotides

KW - Oligonucleotides, Antisense

U2 - 10.1089/1545457041526281

DO - 10.1089/1545457041526281

M3 - Journal article

C2 - 15294077

VL - 14

SP - 147

EP - 156

JO - Nucleic Acid Therapeutics

JF - Nucleic Acid Therapeutics

SN - 2159-3337

IS - 2

ER -

ID: 59324243